BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 15323142)

  • 21. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
    Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas.
    Nizzoli R; Bozzetti C; Crafa P; Naldi N; Guazzi A; Di Blasio B; Camisa R; Cascinu S
    Diagn Cytopathol; 2003 Mar; 28(3):142-6. PubMed ID: 12619096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
    Rhodes A; Jasani B; Couturier J; McKinley MJ; Morgan JM; Dodson AR; Navabi H; Miller KD; Balaton AJ
    Am J Clin Pathol; 2002 Jan; 117(1):81-9. PubMed ID: 11789735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
    Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
    Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
    Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
    Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
    J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma.
    Gong Y; Symmans WF; Krishnamurthy S; Patel S; Sneige N
    Cancer; 2004 Feb; 102(1):34-40. PubMed ID: 14968416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer.
    Zhang D; Salto-Tellez M; Putti TC; Do E; Koay ES
    Mod Pathol; 2003 Jan; 16(1):79-84. PubMed ID: 12527717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.